

AMENDMENTS

Please amend the claims as set forth below:

Claims 1-10 (cancelled)

Claims 11-64 (withdrawn)

65. (currently amended) A method for determining whether a substance inhibits or reduces an inflammatory process in which a macrophage is in a hyperactivated status due to a differentially expressed macrophage surface receptor, comprising: (a) applying said substance to a test system which generates a measurable read-out upon modulation of said macrophage surface receptor or macrophage surface receptor function, wherein said macrophage surface receptor is a FPRL-1 receptor comprising SEQ ID NO:2 or a variant, mutant or fragment thereof having the same function; and (b) comparing the level of the read-out of the test system to a control level, wherein a difference in levels indicates the substance is an inhibitor or an activator of said macrophage surface receptor; and wherein the inhibitor of the macrophage surface receptor which is expressed on a higher level in said hyperactivated macrophage or the activator of the macrophage surface receptor which is expressed on a lower level in said hyperactivated macrophage indicates the substance inhibits or reduces said hyperactivated status of said macrophage.

66. (currently amended) The method according to claim ~~1~~65 in which said receptor is a mammalian receptor.

67. (currently amended) The method according to claim ~~2~~66 in which said receptor is a human receptor.

68. (currently amended) The method according to claim ~~1~~65 in which the test system is a cellular system.

69. (currently amended) The method according to claim ~~4~~68 wherein the cellular system comprises a MonoMac6 cell or a THP-1 cell, and wherein said cell is stimulated with phorbol 12-myristate 13-acetate and with a substance selected from the group consisting of LPS and smoke.

Claims 70-71 (cancelled)

72. (currently amended) The method according to claim 765 in which said receptor is
C¹ FPRL-1 receptor (SEQ ID NO:2).

Claim 73 (cancelled)
